Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: AIDS. 2009 Feb 20;23(4):461–469. doi: 10.1097/QAD.0b013e32831db217

Table 2. Impact of aciclovir on genital and plasma HIV-1 RNA, genital HSV-2 DNA, and CD4+ cell count at month 3 (M3) visit.

Aciclovir
(N=134*)		 Placebo
(N=137*)		 Measure of effect**
(95%CI)		 p-value
HIV-1 RNA
Women with detectable genital HIV-1 RNA 61 (46%) 71 (52%) RR = 0.89 (0.70 to 1.14) 0.36
Mean genital HIV-1 RNA (SD) among women
with detectable HIV-1 RNA, log10 copies/mL		 3.20 (0.87) 3.12 (0.81) 0.13 (−0.14 to 0.39) 0.35
Mean plasma HIV-1 RNA (SD), log10 copies/mL 3.66 (1.16) 3.90 (1.07) −0.34 (−0.54 to −0.15) 0.001
Median CD4 cell count (IQR), cells/mm3 405 (300-522) 435 (329-632) 7 (−24 to 37) 0.66
HSV-2 DNA
Women with detectable genital HSV-2 DNA 10 (8%) 28 (20%) RR = 0.37 (0.19 to 0.73) 0.002
Mean genital HSV-2 DNA (SD) among women
with detectable HSV-2 DNA, log10 copies/mL		 3.80 (1.72) 3.62 (1.82) 0.16 (−1.23 to 1.54) 0.82
*

For aciclovir, there were 2 missing values for genital HIV-1 RNA and 1 missing value for genital HSV-2 DNA For placebo, there was 1 missing value for plasma HIV-1 RNA and 4 missing values for CD4 cell count

**

Risk ratios or mean differences. Mean difference outcomes adjusted for baseline values CI, confidence interval; RR, risk ratio; SD, standard deviation